Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Common Stock, $0.00001 par value per share
-
Shares outstanding
-
165,547,872
-
Total 13F shares
-
55,789,405
-
Share change
-
+1,409,630
-
Total reported value
-
$353,148,555
-
Put/Call ratio
-
243%
-
Price per share
-
$6.33
-
Number of holders
-
115
-
Value change
-
-$140,688
-
Number of buys
-
63
-
Number of sells
-
49
Institutional Holders of CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) as of Q2 2021
As of 30 Jun 2021 CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) had 115 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 55,789,405 shares of stock of the company.
Largest 10 holders included Point72 Asset Management, L.P., VANGUARD GROUP INC, BlackRock Inc., STATE STREET CORP, RA CAPITAL MANAGEMENT, L.P., VICTORY CAPITAL MANAGEMENT INC, Candriam Luxembourg S.C.A., PERCEPTIVE ADVISORS LLC, ORBIMED ADVISORS LLC, and JACOBS LEVY EQUITY MANAGEMENT, INC.
This table shows 115 institutional shareholders of the security as of 30 Jun 2021.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.